A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

3期 已完成 NCT05218655

摘要

The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Baseline (Day 1) up to 30 days after last dose of study drug (956 days) · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
• Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
• Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
• Maintenance TMS in Treatment Resistant Depression — Austin Messner

全部试验